To assess theefficiency of these new inhibitors in a clinicallyrelevant model, we tested the potency of the three sulfamate analogues(3c–3e) along with ibrutinib and 3a in chronic lymphocytic leukemia (CLL) primary patient samplesfor the inhibition of BTK phosphorylation and its downstream pathwaytargets pPLCγ2, pAkt, and pERK.41 CLL cells (20 × 106/mL) were incubatedwith DMSO, ibrutinib, or ibrutinib-based sulfamates (3c–3e) at the indicated doses at 37 °C. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.